The Board of Directors approved the consolidated accounts as of the end of June 2022 at its meeting held on 13th October 2022. The audit procedures on the consolidated accounts have been carried out. The auditors’ certification report will be issued after finalization of the verification of the management report and the procedures required for the purposes of filing the universal registration document.
The consolidated financial statements and reports will be available to the public when the company's universal registration document is published at the end of October 2022.
| In € million | From 1 July 2021 to 30 June 2022 | From 1 July 2020 to 30 June 2021 | Variation |
| Île-de-France | 1,057.9 | 1,000.8 | +5.7% |
| Auvergne-Rhône-Alpes | 579.6 | 561.7 | +3.2% |
| Hauts de France | 393.4 | 380.6 | +3.4% |
| Provence Alpes Côte d'Azur | 169.1 | 161.4 | +4.8% |
| Bourgogne Franche Comté | 133.7 | 134.3 | -0.4% |
| Other regions | 669.8 | 655.3 | +2.2% |
| Nordic countries | 1297.4 | 1,155.4 | +12.3% |
| Reported Turnover | 4,301.0 | 4,022.6 | +6.9% |
Note: The table above details the contributions of the various operating segments to the Group's consolidated turnover.Changes in reported turnover from the financial year ended 30 June 2021 to the the financial year ended 30 June 2022. | Reported Turnover 30 June 2021 | Changes in foreign exchange | Acquisitions and disposals- | Organic growth | Reported turnover 30 June 2022 | Variation |
| In € million |
| 4,022.6 | (12.9) | +53.7 | +237.6 | 4,301.0 | +278.4 |
| | -0.3% | +1.3% | +5.9% | | +6.9% |
Significant events of the financial year:Health crisis due to the COVID PandemicThe financial year ending June 30th 2022 was impacted by the ongoing health crisis due to the COVID pandemic in all countries where the Group operates.
FranceIn France, private hospitals have maintained their action plans to combat the COVID epidemic and their level of investment in conjunction with and in support of public hospitals, in accordance with the national health plan.
Ramsay Santé upheld its commitment to treating COVID patients with more than 10,000 COVID patients treated in France, including 4,500 in critical care. Like other hospital operators, Ramsay Santé has continued to be supported by measures implemented by the government. The main measures during the period concern:
- The revenue guarantee
- Grants compensating for additional costs related to COVID
The revenue guarantee covered the entire financial year for Medicine, Surgery and Obstetrics (MSO) and Follow-up Care and Rehabilitation (FCR). It was only in place for the first half of the year (July-December 2021) for Mental Health activities, given the reform of the financing of Mental Health activities (MH) towards an allocation model in force since January 1st 2022.
The amount of the funding guarantee recognised by the Group for the year ending June 30th 2022 amounts to €99 million (€103 million for the previous year) and is reported in the income statement under “Other operating income”.
In addition to the revenue guarantee, the government also adjusted the levels of grants usually paid to health care institutions in order to compensate for the additional costs related to the COVID crisis that would not otherwise be covered. These subsidies are reported in the income statement under “Other operating income” for €89.8 million (€72.3 million for the previous financial year). Given the time lag between when costs are incurred by facilities and notification by the Regional Health Authorities of the corresponding subsidies, a significant portion of the subsidies reported during the period corresponds to financing for additional costs incurred during the previous financial year, a situation similar to that of the same period last year. Of the total amount of funding recognised in the period, €27.5 million (€14.5 million in the previous year) corresponds to amounts received for the funding of additional costs incurred in the previous year.
Outside FranceThe Group's facilities in Scandinavia played an active role in the care of COVID patients as well as in screening and vaccinating the population, backing up public institutions and in close collaboration with the supervisory authorities. Nevertheless, activity was impacted by the health crisis during the period, in particular for inpatient care in Sweden but also in Denmark and Norway where the authorities suspended admissions at the height of the spread of the virus from December 2021 to February 2022. Despite these periods of disruption, the overall activity level and profits were strong as activity was boosted during the periods when normal activity resumed.
In Sweden, Sankt Göran Hospital and the Group-operated geriatric hospitals in Stockholm played a key role in managing the outbreak with over 100 beds dedicated to COVID patients. Sankt Göran, together with the Stockholm geriatric hospitals, treated almost 20% of all COVID patients in the Stockholm area throughout the pandemic. The Group contributed significantly to the screening and vaccination effort in Sweden and to screening in Norway.
Whilst no support measures were implemented in Norway and Denmark, our facilities in Sweden received grants to cover additional operating costs. In total, the amount of aid received by our institutions in Sweden was €32.2 million in the period, compared to €61.5 million in the previous period.
Scope of consolidationRamsay Santé finalised the acquisition of 10 entities in Scandinavia during the year. These acquisitions are complementary to the current business and expand the scope of the Group's services as well as its geographic footprint. In total, these acquisitions represented a net investment of €288.6 million.
Furthermore, Ramsay Santé completed the acquisition of GHP Specialty Care AB (“GHP”) in May 2022, for an enterprise value of €238 million. In the 12 months ending December 2021, GHP's turnover amounted to €137 million. GHP employs 765 FTEs. This acquisition contributed €29 million in turnover and €1.9 million in EBITDA to Ramsay Santé's accounts in the year ended 30 June 2022.
Comments on the annual accountsActivity and turnover:In the financial year ending June 30th 2022, Ramsay Santé Group reported a consolidated turnover of €4,301.0 million, compared with €4,022.6 million for the period from July 1st 2020 to June 30th 2021, an increase of 6.9%. Please note that the financing guarantee scheme in the Group's accounts has no impact on reported turnover as it is reported in the income statement under “Other operating income”.
On a like-for-like basis and at constant exchange rates, the Group’s turnover increased by 6.0% with one additional working day.
Changes in the scope of consolidation are due to divestment of the German business and two clinics in France in the previous financial year, combined with acquisitions in the Nordic region over the last 12 months.
For the financial year ending June 30th 2022, the overall activity of Ramsay Santé’s French entities continued to be impacted by the consequences of the COVID pandemic. The main effects were related to the cancellation of certain scheduled medical and surgical activities during the peaks of the pandemic but also from limiting the number of patients per room. In total, the number of patient admissions increased by 3.2% compared with last year. This increase is mainly related to comparatively lower volumes in 2020-2021, as the negative impact of the COVID pandemic on patients' willingness to access care recedes in our follow-up care, rehabilitation and mental health activities.
The variation by business line breaks down as follows:
- +0.3% in medicine, surgery and obstetrics
- +23.8% in follow-up care and rehabilitation
- +11,4% in mental health
As part of its public service missions, the Group recorded a 16.2% increase in the number of emergency room visits during the past year, with approximately 755,000 visits to our facilities in France.
Organic turnover growth in Nordic countries for the year ending June 30th 2022 was +7.4% compared with last year. Organic turnover growth was boosted by both investments and new contracts, additional services related to COVID screening and vaccination, and continued positive turnover growth in the underlying business. Scandinavian business also benefited from the latest acquisitions, which contributed €66 million of additional turnover during the financial year, net of the impact of disposals (German business sold at the end of 2020).
Results:EBITDA reached €658.4 million for the financial year ending June 30th 2022, up 2.3% on a reported basis. The Group's EBITDA at 30 June 2022 includes 99.1 million related to the revenue guarantee system described in the paragraph “Significant events of the financial year” above, as well as cost compensations for COVID surcharges for France and Sweden. EBITDA was also positively impacted by the organic growth of the business, particularly in the Nordic region.
The EBITDA margin as a percentage of turnover was 15.3%, compared with 16.0% for the same period last year on a reported basis.
Underlying operating profit amounted to €281.1 million between July 1st 2021 and June 30th 2022 (or 6.5% of turnover), up 3.3% on the previous year.
Other non-current income and expenses represent a net income of €10.2 million for the period ending June 30th 2022, consisting mainly of gains on the disposal of vacant real estate assets, divestments of tangible and intangible assets, and release of provisions related to the disposal of Capio's business in Germany. From July 1st 2020 to June 30th 2021, other non-current income and expenses represented a net expense of €21.4 million.
The cost of net financial debt amounted to €123.5 million for the year ending June 30th 2022, compared with €123.2 million the previous year. This includes interest on Senior debt and, in accordance with IFRS 16, the Group recorded a financial interest expense of €72.3 million related to lease debt (€71.1 million the previous year).
The Group’s share of net income for the period from July 1st 2021 to June 30th 2022 amounted to €118.4 million, or 2.8% of turnover, compared with €65.0 million for the period from July 1st 2020 to June 30th 2021.
Financing:Net financial debt on June 30th 2022 was €3,709.9 million compared with €3,230.5 million on June 30th 2021. Net debt includes €1,763.6 million in non-current borrowings and €35.4 million in current borrowings, offset by €132,5 million in cash and cash equivalents.
The application of IFRS 16 to operating leases contributed €2,118.3 million to net financial debt at June 30th, of which €1,922.3 million was non-current lease debt and €196.0 million was current lease debt.
During the first half of this fiscal year, Ramsay Santé carried out a Euro Private Placement bond issue for a total financing amount of €100 million on two tranches maturing in 2027 and 2028.
During the second half of this fiscal year, Ramsay Santé has drawn €100 million from its revolving credit facility which was then fully repaid before 30 June 2022. The Group complies with all commitments relating to the financing documentation in place. The application of IFRS 16 has no effect on the methods used to calculate the financial aggregates referred to in these debt agreements.
Subsequent events :Extension of the 2022 revenue guarantee – 24 August 2022 decreeThe French government has issued a decree on 24 August 2022 modifying the 10 May 2022 decree related to the revenue guarantee in favour of healthcare facilities in order to cope with the COVID-19 pandemic for 2022. The 24 August 2022 decree extends the 2022 revenue guarantee to 31 December 2022: terms of the initial decree 10 May 2022 are modified to cover a 12-months period ending 31 December 2022, the mechanism of the scheme being otherwise maintained.
Additional €150 million funding within the Fiducie SûretéRamsay Santé has concluded an additional €150 million loan agreement within its Fiducie Sûreté (created in 2018) becoming one of the largest Fiducies-Sûreté (€318 million in cumulative outstanding loans) in the French market and the first one indexed to ESG criteria.
Immobilière de Santé, the main holding company for the equity and/or real estate assets of Ramsay Santé, leader in private hospitalization and primary care in Europe, has entered into an additional loan agreement (Tranche 3) for a principal amount of €150 million. Arranged by Natixis (advised by CMS Francis Lefebvre Avocats), the transaction was supported by a pool of lenders composed of various entities of Groupe BPCE, La Banque Postale and BPIFRANCE.
This long-term financing, which is intended to finance the general needs of Immobilière de Santé and the Ramsay Santé group, is backed by a fiducie sûreté covering the shares of real estate subsidiaries holding the buildings of 6 private hospitals or clinics, for which Natixis is the trustee.
This reloading of our real estate financing vehicle is fully in line with the sustainable development strategy of the Ramsay Santé group on three levels:
- To diversify and extend the average maturity of its debt at an attractive financing rate in a financial market environment that is currently particularly constrained,
- To continue with the group's strategy of developing our real estate assets, while having a better balance sheet correlation between the asset and liability items of the Ramsay Santé group,
- Continue the efforts of the Group's CSR strategy, which includes an ambitious environmental responsibility component.
Reminder of the previous communication relating to the indicative offer received by RHC Limited
Ramsay Health Care has published a new press release on 26 september 2022 informing of the end of the discussions with the consortium led by KKR.
The full press release issued by Ramsay Health Care Limited can be viewed
on the Ramsay Health Care Limited website.